LivaNova plc Stock
LivaNova plc Stock
LivaNova plc shows a slight decrease today, losing -€0.500 (-0.680%) compared to yesterday.
LivaNova plc is currently one of the favorites of our community with 13 Buy predictions and no Sell predictions.
On the other hand, the target price of 72 € is below the current price of 73.5 € for LivaNova plc, so the potential is actually -2.04%.
So far the community has only identified positive things for LivaNova plc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of LivaNova plc in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of LivaNova plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| LivaNova plc | -0.680% | 4.255% | 0.685% | 103.039% | 40.000% | 45.545% | 5.755% |
| Haemonetics Corp. | 5.520% | 1.370% | 12.121% | - | 8.029% | - | - |
| Bio-Rad Labs Inc. A | 0.470% | 4.059% | 13.946% | 31.071% | 15.316% | -18.162% | -53.891% |
| Penumbra Inc | -0.070% | 0.795% | 0.432% | 36.364% | 4.730% | 22.368% | 23.670% |
Comments
LivaNova (LIVN) had its price target raised by Needham & Company LLC from $81.00 to $93.00. They now have a "buy" rating on the stock.
Show more
Ratings data for LIVN provided by MarketBeat
LivaNova (LIVN) had its "overweight" rating reaffirmed by KeyCorp. They now have a $92.00 price target on the stock.
Show more
Ratings data for LIVN provided by MarketBeat
LivaNova (LIVN) had its price target lowered by Robert W. Baird from $78.00 to $76.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for LIVN provided by MarketBeat
News
LivaNova Q2 Earnings Call Highlights
Key Points
- Interested in LivaNova PLC? Here are five stocks we like better.
- Record Q2 performance: Revenue rose 9.8% year over year on a constant-currency basis to $391 million, while adjusted
